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IMPACT OF THE 2014 NCCN GUIDELINES FOR GENETIC TESTING ON 
AN ACADEMIC GYNECOLOGIC ONCOLOGY PRACTICE 
 
KRISTIN HEHIR 
ABSTRACT 
Objective: To determine the impact the change in NCCN guidelines for genetic 
counseling had on an academic Gynecologic Oncology practice. Further, to 
evaluate the patients being referred and the effectiveness of the genetic 
counseling referral process for ovarian cancer patients.  
Design: A retrospective medical chart review was conducted of new ovarian 
cancer patients seen prior to (n=144) and following (n=173) the change in 
guidelines. Data such as cancer diagnosis, age at diagnosis, cancer family history, 
referral for genetic counseling, genetic counseling date, and genetic testing type 
was collected. Data was coded and analyzed using descriptive statistics and SPSS 
to determine if there was a statistically significant change before and after the 
guidelines publication. 
Results: The referral rate for genetic counseling from January-March 2013 was 
determined to be 52% and in 2014 was 83.3%. This showed a 31.3% increase in 
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genetic counseling referrals (p=.019).  However, there were still patients not 
being referred and some patients did not have complete genetic testing.  
Discussion: The change in NCCN guidelines did have an impact on patient care 
in this academic gynecologic oncology clinic. An effective referral system needs 
to be set up not only for new patients, but also for established patients who never 
had genetic testing or had incomplete testing.  
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INTRODUCTION 
 
 Epithelial ovarian cancer accounts for about 224,000 new cases of cancer 
per year and causes over 14,000 deaths per year. It is the tenth most common 
female cancer and the fifth in mortality rate (Figure 1) (Siegel et al., 2013). This 
demonstrates that ovarian cancer is a common and deadly cancer, which poses a 
public health issue that needs to be addressed. The high death rate is partially 
due to the cancer being diagnosed in late stages. Not only are there not adequate 
screening methods, but the symptoms of ovarian cancer can easily go un-noticed 
or be mistaken for other medical issues.  The most common symptoms of ovarian 
cancer are bloating, abdominal pain, menstrual cycle changes, and urinary 
symptoms. While these symptoms can be identified, they are not unique to 
ovarian cancer and therefore make it difficult to diagnosis early. Typically by the 
time symptoms are noticed, the cancer has already spread (Jayson et al., 2014). 
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Figure 1. Top Ten Cancer Incidence and Death Rates by Gender.  
Figure taken from Cancer Statistics in CA: A Cancer Journal for Clinicians. 
Ovarian cancer is the tenth most common cancer and the fifth most common 
cause of death due to cancer among women.  
  
The death rate of ovarian cancer has not significantly declined over the 
last 30 years despite the fact that there has been development of new therapies 
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(Siegel et al., 2013). In comparison, the death rate of breast cancer has dropped 
34% over the past 20 years (DeSantis et al., 2014). This decrease could be 
attributed to increased screening by mammograms resulting in early diagnosis 
and improved survival or the development of more effective therapies.  
Diagnosing cancer at early stages is critical to overall survival. The five-year 
survival rate for stage one ovarian cancer is 90%; however only 15% of ovarian 
cancers are diagnosed at stage one. The majority of ovarian cancers are 
diagnosed at stage three and the five-year survival is only 50% (American Cancer 
Society, 2014). In comparison, the majority (61%) of breast cancers are diagnosed 
at stage one for which the five year survival rate is 98.5% (National Cancer 
Institute, 2011). Not only are more breast cancers diagnosed at earlier stages than 
ovarian cancer, but the survival rate at each stage is also superior.  
Currently the only screening methods for ovarian cancer are pelvic exams, 
transvaginal ultrasounds, and measuring the tumor marker CA-125 in the blood 
(National Cancer Institute, 2014). CA-125 is a plasma protein that can be 
measured in the blood and can be used as a tumor marker for ovarian cancer. In 
many women with ovarian cancer CA-125 will be high and if their treatment is 
effective then there will be a drop in this tumor marker. However, not every 
woman with ovarian cancer has a high Ca-125 and sometimes healthy women 
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will have a high CA-125 (American Cancer Society, 2015). This makes it difficult 
to use CA-125 to detect ovarian cancer. In one study, it found that screening 
healthy women with CA-125 and transvaginal ultrasound leads to increased 
testing and surgeries, but did not have an impact on decreasing deaths from 
ovarian cancer (Fung et al., 2004). Therefore, it has been debated if these methods 
are valuable tools to recommend to patients. At the present time these screening 
methods are not used in the general population. 
On the other hand, screening for breast cancer by mammography is used 
widely. For women without family history, mammograms are recommended on 
a personal basis for ages 40-49 and every two years for ages 50-74 (Nelson et al., 
2009). This is recommended because there is a phase in breast cancer in which 
one is asymptomatic, but mammograms can typically detect the cancer (Harris et 
al., 2011). It has been found that for women ages 39-49 screening by 
mammograms will reduce a woman’s mortality by breast cancer by 15% (Nelson 
et al., 2009). However, there are negatives to mammograms such as false 
positives, pain during the procedure, radiation exposure, and anxiety or stress. 
Nonetheless, preventing breast cancer outweighs the negatives of mammograms 
for most women and the majority of women over the age of 40 decide to have 
annual mammograms (Pace et al., 2013). This demonstrates that in order to 
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decrease the mortality due to ovarian cancer, a more effective screening method 
needs to be developed. 
Ovarian cancer is indisputably a difficult disease to treat, especially at late 
stages. There is a need for improved screening and prevention; however this has 
clearly been a challenging task to accomplish. The survival from ovarian cancer 
is especially poor once recurrence has occurred and about 71% will relapse at 
some point (National Cancer Institute, 2014). The median progression free-
survival from ovarian cancer is about 18 months, which is not a desirable 
prognosis (Jayson et al., 2014). Clearly, there is a need to determine how to 
prevent and detect ovarian cancer in order to make progress with this difficult 
health issue.  
Risk Factors for Ovarian Cancer 
 Risk factors for ovarian cancer include early menarche, late menopause, 
nullparity, obesity, personal history of breast cancer, and family history (Hunn & 
Rodriguez, 2012). Family history of ovarian cancer is the most influential risk 
factor in predicting if an individual will develop ovarian cancer in her lifetime. If 
someone has a first degree relative with ovarian cancer then her lifetime risk 
increases from 1.4% to 5%. That risk will then increase to 7% if there are 2 or 
more first degree relatives (Weissman et al., 2012). Accurate intake of family 
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history is especially crucial in ovarian cancer patients to help determine if there 
could be a hereditary factor that is related to their cancer.   
 One of the reasons family history is such an influential risk factor for 
ovarian cancer is the fact that there could be an underlying genetic mutation that 
increases one’s risk for ovarian cancer. It used to be thought that about 1 in every 
10 women with ovarian cancer has a hereditary mutation. Over time that number 
has increased and currently data shows that about 1 in every 4-5 women with 
ovarian cancer carries a hereditary mutation (Weissman et al., 2012). This is 
compared to only 5-7% or 1 in every 14-20 women with breast cancer is found to 
have a hereditary mutation (Gage et al., 2012). In a short period of time the 
number of genes linked to ovarian cancer has grown. Presently, there are at least 
16 genes that have been shown to confer an increased risk of hereditary ovarian 
cancer (Pennington et al., 2012).  
 Identifying genetic mutations in women with ovarian cancer is crucial 
since it has been proposed that greater than 30% of women with inherited 
mutations have no family history of breast or ovarian cancer (Walsh et al., 2011). 
Without finding these mutations in the affected individual there would be no 
reason to believe that these families are at high risk for ovarian cancer. The lack 
of family history in families with inherited mutations can partially be explained 
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by small families, lack of information, male dominated families, or inheritance 
from unaffected fathers.  
 The phenotype of hereditary breast and ovarian cancer syndrome (HBOC) 
includes young age at diagnosis, individuals with multiple primaries, bilateral 
breast cancer, male breast cancer and first or second degree relatives with these 
same cancers. HBOC is due to an inherited mutation that is passed on in an 
autosomal dominant pattern. This means that the mutation is not sex linked and 
the individual only needs one copy of the gene to be at increased risk (Powers & 
Stopfer, 2014). If a parent is heterozygous for a mutated copy of one of these 
genes then his or her children each has a 50% chance of inheriting that mutation. 
The only way to identify an inherited mutation is by genetic testing to analyze 
one’s DNA to determine if there is a pathogenic mutation in a particular gene.   
 Identifying genetic mutations is important because there is then the ability 
to take action to reduce one’s risk of cancer. Patients are encouraged to increase 
screening, use chemo-preventative measures, and have prophylactic surgeries. 
For example, patients with a BRCA 1 or BRCA2 mutation are recommended to 
have a prophylactic mastectomy and salpingo-oophorectomy. It is predicted that 
women undergoing both of these surgeries will have life expectancy gain of 3.3-
11.7 years (Salhab et al., 2010). This demonstrates that identifying these 
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mutations early can allow action to be made in order to decrease the risk for 
cancer.  
BRCA1 and BRCA2 
 The BRCA1 gene codes for a tumor suppressor protein that was 
discovered in 1990 and later cloned in 1994. BRCA1 is situated on the long q arm 
of chromosome 17 and translates into a predicted protein consisting of 1863 
amino acids. The protein contains a zinc finger (Miki et al., 1994). The BRCA1 
gene is expressed in breast, ovarian, and other related tissues. BRCA1 is 
responsible for maintaining chromosomal stability, sensing cell damage, and is 
involved in cell cycle checkpoints (Venkitaraman, 2002). In particular, BRCA1 is 
involved with repairing DNA double strand breaks through homologous 
recombination (Gudmundsdottir & Ashworth, 2006). Homologous 
recombination is an accurate method of DNA repair and essential to ensuring 
DNA stability. It was shown that mice deficient in BRCA1 were unable to repair 
DSBs by homologous recombination (Moynahan et al., 1999). The many roles of 
the BRCA1 protein are critical in preventing a cell from developing into a 
cancerous cell by assisting with DNA stability. The loss of a tumor suppressor 
protein such as BRCA1 will accelerate the development of cancer.  
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 BRCA2 is also a tumor suppressor protein that is located on the q arm of 
chromosome 13 and encodes for a protein consisting of 3418 amino acids 
(Wooster et al., 1995). The gene was first discovered in 1994 a few years after 
BRCA1. BRCA2 is mostly expressed in breast and ovarian tissue, but is found in 
other tissues. BRCA2 plays an important role in repairing DNA double strand 
breaks and specifically acts through RAD51 (Gudmundsdottir & Ashworth, 
2006). BRCA2 binds directly to RAD51 and this interaction is critical to identify 
DSBs (Davies et al., 2001). BRCA1/2 play important roles in the interaction with 
the Fanconi Anemia pathway, which controls the cell’s response to DNA damage 
(Figure 2) (D’Andrea & Grompe, 2003). Similar to BRCA1, the loss of BRCA2 will 
lead to DNA instability and accelerate the transformation of a cell from normal to 
cancerous.  
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Figure 2. The Fanconi Anemia & BRCA Pathway. 
Figure taken from D’Andrea & Grompe (2003). The Fanconi Anemia pathway is 
activated upon DNA damage and interacts with BRCA1/2 in vivo. 
 
Individuals will inherit one copy of each of the BRCA genes from their 
parents. Carriers of BRCA1 mutations are thought to have a lifetime breast 
cancer risk of 55-65% and ovarian cancer risk of 39-49%. Similarly, BRCA2 
mutations will have a lifetime risk of breast cancer between 45-47% and ovarian 
cancer risk of 11-18% (Girolimetti et al., 2014). The BRCA1/2 genes are of high 
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penetrance (Chen & Parmigiani, 2007).  BRCA1/2 are thought to account for the 
majority (about 50-80%) of hereditary breast and ovarian cancer families. It is 
estimated that BRCA1/2 mutations occur in about 1 in 400 individuals in the 
population, but this number depends on ethnicity (Petrucelli et al., 2013). In 
general, BRCA1/2 mutations are rare in the general population, but more 
common in families with compelling breast and ovarian cancer history.   
Lynch Syndrome 
 Lynch syndrome is caused by mutations in germline mismatch repair 
genes such as MLH1, MSH2, MSH6, or PMS2. Mutations in these genes are 
inherited in an autosomal dominant pattern (Cohen & Leininger, 2014). 
Mismatch repair is a process that occurs in cells to help preserve DNA. If 
incorrect nucleotides are connected they can be identified and fixed by mismatch 
repair proteins. This process requires the coordination of many proteins. If one of 
those proteins is not functional then it leads to the inability to correct these 
changes and eventually unstable DNA (Zhang et al., 2015).  
Lynch syndrome is also called Hereditary Nonpolyposis Colorectal 
Cancer. Individuals with Lynch syndrome are at a high risk for colon cancer, 
endometrial cancer, ovarian cancer, and stomach cancer. There is an 80% risk of 
developing colon cancer and the majority of these occur in the proximal colon. 
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The lifetime risk of ovarian cancer is anywhere from 4-11% (Weissman et al., 
2012). It is believed that about 2-4% of ovarian cancer is due to inherited 
mutations in mismatch repair genes (Malander et al., 2006). If a family has colon 
and ovarian cancer history then Lynch Syndrome definitely needs to be 
considered.  
TP53 
 TP53 is located on the short arm of chromosome 17 and encodes for the 
transcription factor protein p53 (Isobe et al., 1986).  P53 is a key tumor suppressor 
protein that is involved in regulation of the cell cycle, DNA repair, apoptosis, 
and cellular senescence. P53 is normally activated under cell stress and p53 
function is lost in the majority of cancers (Sorrell et al., 2013). P53 plays a key role 
in preventing uncontrolled cell growth; therefore germline TP53 mutations put 
individuals at high risk for many cancers. Germline mutations in TP53 are 
associated with Li-Fraumeni syndrome (Malkin et al., 1990). Penetrance is nearly 
100% by the age of 70 (Mai et al., 2012).  
 Typically Li-Fraumeni syndrome is associated with bone or soft tissue 
sarcomas, adrenal cortical carcinomas, premenopausal breast cancers, and brain 
tumors. It is less frequently associated with ovarian cancer; however it is seen in 
individuals with TP53 mutations (Gonzalez et al., 2009).  
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Moderate Penetrance Genes 
PALB2 
 PALB2 was named that because it stands for “partner and localizer of 
BRCA2”. The main role of PALB2 is to be the binding protein for BRCA2. It is 
believed that about 50% of PALB2 interacts with BRCA2 and vice versa (Xia et 
al., 2006). This indicates that a large portion of PALB2 is needed for the adequate 
function of BRCA2 DNA repair.  
 If one is heterozygous for a PALB2 mutation then it is thought that they 
are at increased risk for cancer. It has been estimated that a female with a 
mutation in PALB2 has a lifetime risk of breast cancer of about 35% (Antoniou et 
al., 2014). Families with PALB2 mutations tend to look like families with BRCA2 
mutations.  
 CHEK2 
 CHEK2 is located on the long arm of chromosome 22 and is a protein 
kinase. CHEK2 is activated when damaged DNA is identified and then will stop 
a cell from going through mitosis (Cybulski et al., 2004). CHEK2 acts through the 
ATM gene. In addition, CHEK2 interacts with BRCA1, BRCA2, and TP53 in vivo 
and helps to ensure DNA stability.  
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 CHEK2 is expressed in many tissues and has been associated with 
increased risk for cancer. In particular, CHEK2 has been estimated to increase 
one’s breast cancer risk by 2 fold (Walsh et al., 2006). CHEK2 mutations have also 
been associated with ovarian cancer, but the exact risk is not known (Walsh et al., 
2011).  
 PTEN 
 PTEN is located on the q arm of chromosome 10 and encodes for a tumor 
suppressor protein (Steck et al., 1997). PTEN is expressed throughout various 
tissues in the body and acts through its phosphatase product to control the cell 
cycle (Chu & Tarnawski, 2004). Mutations in PTEN result in Cowden’s 
Syndrome, which is autosomal dominant. Cowden’s syndrome is typically 
associated with benign characteristics such as macrocephaly, uterine fibroids, or 
fibrocystic breasts (Eng, 2000). PTEN is commonly mutated in cancer and people 
with germline mutations have an elevated risk for breast, endometrial, colorectal, 
thyroid, and kidney cancers (Tan et al., 2012). Cases of individuals with PTEN 
mutations and ovarian cancer have been reported (Walsh et al., 2011).  
 ATM 
 ATM is located on the q arm of chromosome 11and encodes for a protein 
that is 3056 amino acids long (Shiloh, 2003). The main function of the ATM 
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protein is to control cell division and assists with repairing double strand DNA 
breaks (Ellis & Offit, 2012). Homozygous germline mutations are associated with 
Ataxia-teangiesctasia (AT), which presents during childhood. AT results in 
progressive neurodegeneration, immune defects, and increased risk for cancer 
(McKinnon, 2004).  Individuals who are heterozygous for ATM mutations are at 
risk for breast and pancreatic cancer (Geoffroy-Perez et al., 2001). ATM 
mutations have been reported in cases of ovarian cancer; however the exact risk 
is not known.  
Other Genes  
RAD51C 
 The RAD51 gene is thought to be involved in DNA repair by homologous 
recombination. In one study they found a RAD51C mutation in 1.3% of families 
with both breast and ovarian cancer (Meindl et al., 2010). Another study looking 
at probands with ovarian cancer found a RAD51C mutation in 2/360 participants 
(Walsh, 2011). Currently the exact cancer risk associated with RAD51C is not 
defined, but it is thought to elevate one’s risk for breast and ovarian cancer.  
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 RAD51D 
  RAD51D is also involved in the Fanconi Anemia pathway and is 
involved with DNA repair. Mutations in RAD51D have been seen in highly 
penetrant breast and ovarian families (Pennington et al., 2012). 
 MUTYH 
  MUTYH is located on the short arm of chromosome 1 and is 
involved in base excision repair. Base excision repair is a process that fixes 
damaged DNA from reactive oxygen species. MUTYH is one of the many 
proteins involved in this pathway and helps to initiate this process (Cheadle & 
Sampson, 2003). MUTYH is important in ensuring stable DNA is maintained.  
 Individuals who are homozygous for the MUTYH mutation have 
MUTYH-associated polyposis (MAP). Individuals with MAP are at an 80% 
chance of developing colorectal cancer (Jenkins et al., 2006).   If one is 
heterozygous for the MUTYH mutation then they are thought to have an 
increased risk of breast, stomach, and endometrial cancer (Rennert et al., 2012) 
(Win et al., 2011). MUTYH mutations have been reported in families with 
ovarian cancer, but the exact risk is not known (Walsh et al., 2011).  
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 BRIP1 
 BRIP1 is located on chromosome 17 and encodes for a tumor suppressor 
protein (Walsh et al., 2010). BRIP1 is involved in the Fanconi Anemia pathway 
and interacts with BRCA1 in vivo to help with DNA repair. BRIP1 mutations 
have been seen in individuals with breast and ovarian cancer, but further studies 
need to be done in order to investigate the risk association (Seal et al., 2006).  
Genetic Counseling 
 Genetic counseling is a time intensive process in which detailed family 
history is taken, patients are counseled on the meaning of mutations, the various 
test types available are discussed, and genetic testing is coordinated if desired. A 
typical genetic counseling visit will require at least one hour with a genetic 
counselor or genetics trained professional.  
Family History Intake 
The most important task of the genetic counselor is to obtain an accurate 
and thorough family history with a focus on cancer. It is suggested that the 
genetic counselor obtain at least three generations on both the maternal and 
paternal side of the family. This is typically recorded as a pedigree, which can 
help identify patterns that indicate an inherited cancer syndrome (Powers & 
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Stopfer, 2014). This is a time intensive process that most physicians do not have 
the time to coordinate.  
 Some families have striking family histories that are easily identifiable; 
however other families are not so obvious. This could be due to lack of accurate 
information, male dominated families, small family size, adoption, or 
interventions that reduce cancer risk (Stopfer, 2000). These factors are all things 
that genetic professionals are used to identifying, but a professional not exposed 
to genetics could easily overlook.  
 Genetics Education 
After the family history intake, the genetic counselor’s role is to provide 
the patient with general genetics information such as pattern of inheritance, the 
implications of an inherited mutation for your family, penetrance of mutations, 
associated risk of various genes, type of testing available, and the various 
classification of results. Currently there are five classifications of results: 
definitely pathogenic, likely pathogenic, uncertain significance, likely not 
pathogenic, not pathogenic or negative (Plon et al., 2008). Patients need to be 
made aware of the various results they could receive before they decide to 
initiate testing. For some individuals, a variant of uncertain significance could be 
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difficult to deal with since it is unclear and they need to be prepared for the 
possibility.  
Most patients have not been exposed to genetics before their visit and 
education is important, in order for them to be able to make an informed 
decision about testing. Ensuring that a patient has a thorough background of the 
implications is crucial before initiating testing because the results could not only 
have medical implications for themselves, but also their family members 
(DeMarco et al., 2007). Patients need to be informed on the meaning and 
limitations of test results before testing occurs (Ballinger, 2012).  
Genetic Testing 
Myraid Genetics was the first lab to offer BRCA testing in the 1990’s. Until 
2013 Myraid Genetics held a patent for BRCA1/2 due to a supreme court ruling 
the patent was removed. Since then there have been an increase in clinical labs 
offering this testing. Most recently, a new technology called Next Generation 
Sequencing has been developed to allow for faster and more cost effective testing 
(Rainville & Rana, 2014). Next generation sequencing is a technology in which 
many sequences of a gene can be looked at in one reaction, which significantly 
decreases the amount of time and labor needed for analyzing one’s genes 
(Hilbers et al., 2013). Due to this development many cancer genetic clinics have 
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been offering panel tests in which genetic testing for multiple genes is ordered in 
one test. This allows patients the option to have 5-43 genes tested at once. The 
panels of genes are normally grouped by cancer syndrome. This type of testing 
allows for more complete testing, but also can be difficult due to the high rate of 
variants of uncertain significance and the lack of clinical information of some 
genes (Figure 3) (Hilbers et al., 2013). Panel testing has made counseling more 
difficult since there is a great need for more clinical information on these genes; 
however it has been helpful for some families in identifying a reason for one’s 
family history of cancer.  
 
Figure 3. Genetic Test Results from BRCA Testing only and Panel Testing. 
Figure taken from Hilbers et al (2013). If one has a panel tests versus only 
BRCA1/2 then there is a much higher chance that a variant of uncertain 
significance will be identified.  
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Disclosure of Test Results 
The genetic counselor also has a critical role in post-test counseling. Their 
job is to disclose the results, explain implications of results, review 
recommendations, and give psychosocial support. If the result is negative then 
the patient must be told that that result is not completely informative. There 
could be other genes not yet identified that could confer increased risk of ovarian 
cancer and they should be encouraged to re-contact the genetic counselor as time 
goes on. This is especially important if there is a change in family history (Riley 
et al., 2012). With the rapid growth of genetic testing it is expected that testing 
and information about genes will be significantly changing in the next decade.  
If the patient has a positive result then they should be advised to come 
back in to clinic for recommendations on screening and prevention. They also 
need to be encouraged to share this information with their family members and 
encourage their family to come in for testing (Riley et al., 2012). This is when the 
psychosocial evaluation is crucial in order to ensure the patient is getting the care 
they need.  
 If the individual has a variant of uncertain significance then surveillance 
should be based on family history and family members would not be 
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recommended for testing unless the variant is reclassified to pathogenic. The 
majority of variants of uncertain significance will be reclassified to negative.  
 The role of the genetic counselor is crucial in cancer genetics, since 
counseling is a time and labor intensive process. One study found that genetic 
counselors spent almost 50% of their time on patient related activities and only 
25% of their time with direct patient contact (McPherson et al., 2008). It is clear 
that the hour the genetic counselor spends with the patient is only a fraction of 
the time that is needed per patient.  
NCCN Guidelines 
 The National Comprehensive Cancer Network (NCCN) is a group of 
various cancer centers across the world that work together to establish guidelines 
for physicians (NCCN Guidelines, 2015). They work to make evidence based 
recommendations in order to improve cancer care. In January 2014, the 
guidelines for patients with ovarian, fallopian tube, or primary peritoneal cancer 
changed from the guidelines published in February 2013. They were updated to 
recommend that all of these patients be referred for genetic testing regardless of 
family history (Minion et al., 2015). However, it is noted that treatment should 
not be delayed due to lack of genetic counseling referral.  
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 The reason for this change was the increasing amount of inherited 
mutations identified in these patients who had no family history (Walsh et al., 
2011). Missing an inherited mutation in a family could lead to the lost 
opportunity for cancer risk-reducing interventions.   The guidelines do not 
indicate what type of testing should be offered to the patient and that decision 
should be left to the genetic professional. Many patients with ovarian cancer 
were diagnosed years ago and have only had limited BRCA1/2 molecular 
analysis, so there is the possibility that patients with certain family histories 
would need to be re-referred to a genetic consultation due to the availability of 
new testing.  
Specific Aims 
 The purpose of this research study is to determine if the changes in the 
NCCN guidelines from January 2014 had any impact on the Gynecologic 
Oncology Clinic at DFCI. In particular, this study is going to investigate whether 
patients with new diagnoses of ovarian, primary peritoneal, or fallopian tube 
cancer are being referred to obtain genetic testing. The amount of time from 
diagnosis to getting testing will be quantified to see if there is a need for a more 
effective referral process. The type of testing that the patient underwent will also 
be examined. The results of this study will quantify the impact of the NCCN 
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guidelines on clinical practice and the effectiveness of the referral process for 
genetic testing.  
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METHODS 
 
Study Design 
 This study is a retrospective medical chart review of approximately 317 
consult adult patients from the gynecologic oncology clinic at Dana Farber 
Cancer Institute (DFCI). This project was reviewed and approved by the 
Institutional Review Board (IRB) at Dana Farber/HCC.  
Data Collection 
 The records from all consult patients seen in the gynecologic oncology 
clinic at DFCI between 01/02/2013 - 03/29/2013 and between 01/02/2014 - 
03/28/2014 were reviewed in order to determine the correct patient population. 
Data was collected from the Partner’s Health Care Longitudinal Medical Record 
Database (LMR). LMR is the electronic medical record and provides general 
patient information, current and past diagnosis and treatment, diagnosis dates, 
healthcare provider, and all medical notes from providers within the Partner’s 
system.   
Data was also confirmed using the DFCI Center for Cancer Genetics and 
Prevention Progeny Database. The Progeny Database is clinical software for 
capturing family history in pedigree format and genetic testing information for 
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patients seen in the Center for Cancer Genetics and Prevention. The database 
tracks general patient information, cancer history, family history, ethnicity, 
genetic testing information, and genetic counselor. Both LMR and the Progeny 
Database are secure and can only be accessed by staff with access codes.  
Patients were eligible for inclusion if (1) they were new patients to the 
gynecologic clinic, (2) had been newly diagnosed with ovarian, primary 
peritoneal, or fallopian tube cancer, and (3) were seen either from January to 
March 2013 or from January to March 2014. This retrospective chart review 
screened a total of 317 consult patients seen in the Gynecologic Oncology Clinic 
at DFCI. It was found that there were 144 consult patients in 2013 and 173 
consult patients in 2014. During January to March 2013, 50 consult patients were 
diagnosed with ovarian, fallopian tube, or primary peritoneal cancer. Similarly 
during January to March 2014, 57 patients had one of these three diagnoses.  
Data was collected on these individuals to determine the date of their 
diagnosis, age at diagnosis, race, cancer type, if they were referred to genetic 
testing, cancer family history, if they had genetic testing, the date of genetic 
testing, and the type of genetic testing. Their diagnosis was confirmed by 
pathology report and genetic test type was confirmed by original copy. Referral 
to genetic testing was specified if it was documented in the medical record.  Out 
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of all the patients whom had documented referral to genetic testing, zero 
declined the appointment as documented in the medical record.   
Data Analysis 
 Data was collected and summarized using standard descriptive statistics. 
Analysis was done using Microsoft Excel 2007 for Windows and statistical 
software IBM SPSS statistics 2014. Univariate analyses were performed using chi 
square tests and independent t tests. A P value of <.05 was considered 
statistically significant.   
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RESULTS 
 
 
 Medical records from a total of 144 Gynecologic oncology patients with a 
new diagnosis of ovarian cancer were reviewed from January 2013-March 2013. 
Of those 144 patients 33 or 22.9% were second opinions who did not establish 
their care at DFCI. 50 or 45% of the patients who established their care at DFCI 
were diagnosed with ovarian, fallopian tube, or primary peritoneal cancer. 
Similarly for 2014, a total of 173 consult patient charts were reviewed from 
January 2014-March 2014. Of those 173 patients 61 or 35.2% were seeking second 
opinions and did not establish their care at DFCI. Of the patients who established 
care at DFCI, 57 or 50.9% were diagnosed with ovarian, fallopian tube, or 
primary peritoneal cancer.  
The baseline characteristics of the patients diagnosed with ovarian, 
fallopian tube, or primary peritoneal cancer were summarized and the 
characteristics are listed in Table 1. The mean age at diagnosis for 2013 was 59.98 
and the median age for 2014was 60.50. The range of age at diagnosis for 2013 was 
61 and the standard deviation was 12.479.  Likewise the mean age at diagnosis 
for 2014 was 58.63, the median was 59. The standard deviation was 10.964. The 
age at diagnosis for 2013 and 2014 were found to be similar. The majority of 
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patients (82%) in 2013 were diagnosed with ovarian cancer and similarly for 2014 
the majority (89.5%) were diagnosed with ovarian cancer.  
Table 1: 
Baseline Characteristics of Patients Seen in the Gynecologic Oncology Clinic 
Variables 
 
 
 
2013 
(N=50) 
2014 
(N=57) 
  Count % Count % 
Age at 
Diagnosis 
<39 
40-49 
50-59 
60-69 
70-79 
80-89 
5 
4 
13 
21 
6 
1 
10% 
85% 
26% 
42% 
12% 
2% 
1 
12 
17 
16 
9 
2 
2% 
21% 
30% 
28% 
16% 
3% 
Cancer Type Ovarian 
Fallopian Tube 
Primary 
Peritoneal 
41 
5 
4 
 
82% 
105 
8% 
51 
5 
1 
 
89% 
9% 
2% 
 
Figure 4 shows a flow chart of the patients seen in the gynecologic 
oncology clinic for January through March of 2013 and 2014. Of the patients 
diagnosed with ovarian, fallopian tube, or primary peritoneal cancer 7 of the 
patients in 2013 and 15 in 2014 had genetic testing prior to diagnosis and were 
excluded. For 2013 prior to the change in NCCN guidelines 26 patients (52.0%) 
were referred to genetic testing and 17 (70.8%) met with a genetic counselor. Of 
the patients who meet with a genetic counselor 15 (88.2%) had genetic testing 
indicating that most patients decide to have genetic testing once they have been 
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referred. One patient declined testing and one patient’s insurance would not 
cover testing. For 2014, 35 patients (83.3%) were referred to genetic testing and 31 
(88.6%) met with a genetic counselor. All 31 patients decided to move forward 
with genetic testing. For 2014 there was a higher rate of referral, but similar to 
2013 once patients were referred, most decided to have testing.  
 
 
Figure 4: Flow chart of medical record review for January-March 2013. 
 
 
 
Consult Patients in 
Gyn. Oncology 
Clinic 
N=144 
Diagnosed with Ovarian, 
Primary Peritoneal, or 
Fallopian Tube Cancer 
N=50 
Not Referred to 
Genetic Counseling 
 
N=17 
Referred to 
Genetic 
Counseling 
N=26 
Genetic Testing 
Prior to 
Diagnosis 
 N=7 
 31 
 
 
Figure 5: Flow chart of medical record review for January-March 2014. 
A Pearson’s chi square test for independence was run to determine if 
patients diagnosed in 2014 were more likely to be referred for genetic counseling 
due to the change in guidelines when compared to 2013. The p-value was found 
to be .019 and therefore is less than .05 and is statistically significant. It can be 
concluded that there was a statistically significant difference in referrals for 
genetic counseling during 2013 and 2014.  
Then we sought to determine whether there was difference in the amount 
of time it took from date of diagnosis to having the patient seen for genetic 
Consult Patients in 
Gyn. Oncology 
Clinic 
N=173 
Diagnosed with Ovarian, 
Primary Peritoneal, or 
Fallopian Tube Cancer 
N=57 
Not Referred to 
Genetic Counseling 
 
N=7 
Referred to 
Genetic 
Counseling 
N=35 
Genetic Testing 
Prior to 
Diagnosis  
N=15 
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counseling. For 2013, the mean time from date of diagnosis to date of genetic 
counseling appointment was 120.41 days with a standard deviation of 145.704. 
The minimum amount of time was zero days and the maximum was 483 days. 
For 2014, the mean time from date of diagnosis to date of genetic counseling 
appointment decreased to 67.32 days with a standard deviation of 68.93. The 
minimum amount of time was 6 days and the maximum was 335 days. An 
independent t-test was run to determine if there was a statistically significant 
difference between the 2013 and 2014 mean time to obtain genetic counseling. It 
was found that p=.172, which is greater than .05 and therefore the difference in 
the means is not statistically significant. This could be due to the fact that there 
was a small sample size. 
Characteristics such as age at diagnosis and family history could affect the 
probability that patients would be referred to genetic counseling. First, the data 
was split up into groupings based on age at diagnosis. The data was grouped 
into age brackets as follows: <49, 50-69, and >70. The results are summarized in 
table 2. For 2013, it was found that the age group <49 and >70 both had a referral 
rate of 71% while the age group 50-69 had a referral rate of 55%. For 2014, the age 
group with the highest referral rate was <49 at 100%. Following that the group of 
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50-69 had an 84% referral rate and >70 had a 67% referral rate. There doesn’t 
seem to be a difference in referral rate based on age at diagnosis.  
Table 2. Genetic Counseling Referral Rate Based on Age at Diagnosis.  
 2013 2014 
Age 
Group 
Referred 
(N=26) 
Not Referred 
(N=17) 
Referred 
(N=35) 
Not Referred 
(N=7) 
 Count % Count % Count % Count % 
>49 
50-69 
<70 
5 
16 
5 
71% 
55% 
71% 
2 
13 
2 
29% 
45% 
29% 
8 
21 
6 
100% 
84% 
67% 
0 
4 
3 
0% 
16% 
33% 
 
 A chi square test of independence was run to determine if there was an 
association between age at diagnosis and referral rate. For 2013, the p value=.593 
which indicates that the difference is not statistically significant, therefore there is 
not an association between referral rate and age at diagnosis. A chi square test 
was run for 2014 and the p value=.110 and therefore there is also not an 
association between referral rate and age at diagnosis.  
The data was then divided by the type of family history of cancer the 
patients had. The categories were breast and ovarian, colon, neither, adopted, or 
family history not obtained. The results are summarized in Table 3 below. It was 
found in 2013 that physicians were slightly more apt to refer patients with breast 
and ovarian family history (76%) than colon family history (71%). Patients with 
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neither family history were typically not referred (33%). For 2014, all patients 
with colon family history were referred and there was an increase of 46% of 
referrals for patients who had neither family history.  
Table 3. Genetic Counseling Referral Rate Based on Family History of Cancer. 
 2013 2014 
Family 
History of 
Cancer 
Referred 
(N=26) 
Not Referred 
(N=17) 
Referred 
(N=35) 
Not Referred 
(N=7) 
 Count % Count % Count % Count % 
BR/OV 
Colon 
Neither 
Adopted 
Not Taken 
16 
5 
4 
1 
0 
76% 
71% 
33%% 
100% 
0% 
5 
2                
8 
0 
2 
24% 
29% 
67% 
0% 
100% 
13 
6 
15 
1 
0 
81% 
100% 
79% 
100% 
0% 
3 
0 
4 
0 
0 
19% 
0% 
21% 
0% 
0% 
 
A chi square test of independence was run to determine if in 2013 and 
2014 patients with family history were more likely to be referred for genetic 
counseling. The p value=.021 and therefore it was statistically significant since it 
was less than .05. A chi square test was run to see if there was an association 
between year of diagnosis and referral rate for patients with no family history. It 
was found to be statistically significant because the p value=.007 and that is less 
than .05. As expected there was a statistically significant difference in referral 
rates for patients without family history diagnosed in 2013 versus 2014.  
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Finally, the type of genetic testing the patients underwent was studied. 
The options for testing were either BRCA1/2 genes, Lynch Syndrome genes, or a 
more comprehensive panel of genes. It was found that in 2013 the majority of 
patients (75%) had testing for the BRCA1/2 genes and only 25% had a panel. 
However, in 2014 there was an increase in panel testing. 67.7% of the patients 
had a panel ordered and only 32.3% of patients had BRCA testing alone.  There 
was a 42.7% increase in panel testing over the course of the year.  
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DISCUSSION 
 
 Mutations in tumor suppressor genes have been linked to ovarian, 
fallopian tube, and primary peritoneal cancer for some time now; however it was 
not until January 2014 that the NCCN recommendations suggested that all 
patients with these diagnoses have genetic counseling regardless of family 
history. In this project we evaluated if the change in guidelines had an effect on 
genetic couseling referrals from the gynecologic oncology clinic.  For 2013 and 
2014 the mean age at diagnosis was very similar (difference of 1.35), regardless it 
was expected that there would be an increase of referrals in 2014. It was found 
that the difference in referral rates based on year was statistically significant. 
There was an increase of 31.3% of patients being offered genetic counseling from 
2013 to 2014. It was expected that the younger age at diagnosis would be more 
likely to be referred; however it was discovered that there was not a statistically 
significant association between age at diagnosis and referral rate. It was expected 
that in 2013 patients with family history would be more likely to be referred, but 
in 2014 there would be the greatest increase in referrals for patients with neither 
family history. There was an increase in referrals for patients without family 
history (46%), and it was found that patients without family history were more 
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likely to be referred in 2014. It was found that overall the change in NCCN 
guidelines did cause an increase in referrals for genetic counseling especially for 
the patients without a family history of cancer.  
 The time from diagnosis to meeting with a genetic counselor decreased 
from 2013 to 2014 by 53.09 days, but this was not found to be a statistically 
significant difference. This could be due to a small sample size. There was also a 
great range of values, which could be due to patient preference. Some patients 
want to meet with the genetic counselor on the same day as their oncologist to 
obtain all of the information at once, while others find it overwhelming and want 
to wait until their treatment is finished.  
 It was expected that there would be an increase in panel testing since 
panels were relatively new in 2013 and more widely used in 2014. It was found 
that there was a 42.7% increase in panel testing in 2014, which is a substantial 
increase. Panels are chosen because many syndromes can be tested for at once 
and most patients’ insurance companies will only pay for one genetic test 
regardless of how many genes were tested. It is expected that as time goes on 
and more information is learned about the individual genes there will be a great 
increase in panel testing, which can help identify mutations in families without a 
clear phenotype.  
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 Limitations 
 One of the largest limitations in this study was the small sample size. Only 
three months of time from each year were reviewed and it would be beneficial to 
study a longer span of time to measure the impact of the guidelines. Since the 
information was only being pulled from the medical record there could have 
been data that was missed or was never documented. Also, if a patient had 
genetic counseling at another institute then that information could have been 
missed if it was not scanned into the medical record. This could have led to 
incomplete data abstraction, which potentially could have skewed the data.  
 Although the number of patient charts that were reviewed was small 
there were still significant conclusions that could be made. It was clear that the 
NCCN guidelines made a difference in the practice of this specific academic 
oncology clinic. It is helpful for these guidelines to be continually updated since 
they do influence patient care. Further, all the patients who were offered genetic 
counseling met with a genetic counselor and only one patient decided to decline 
testing. This shows that most patients would like to know this information for 
themselves and their families. It is critical that an effective genetic counseling 
referral system be established in oncology clinics in order to facilitate testing. 
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Further, oncologists need to be adequately educated on cancer genetics in order 
to make sure all patients that need to be referred are being offered genetic 
counseling.  
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